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Abstract 
 
This paper describes the use of both mammalian and bacterial expression systems as tools to 
study the structural and functional relationships of proteins encoded by cDNAs to both rat and 
human aryl sulfotransferases. In particular, we describe the use of the mammalian COS cell 
system for functional expression studies, and the use of Escherichia coli for the expression and 
purification of a sulfotransferase fusion protein suitable as an antigen for the generation of 
sulfotransferase antibodies. 
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Sulfotransferases (STs) comprise a superfamily of structurally and functionally related isoforms which are involved 
in the sulfation of a diverse range of exogenous and endogenous compounds including biogenic amines, steroids, 
hormones, and a variety of xenobiotic compounds including drugs and carcinogens [1]. Although generally thought 
of as a detoxification pathway, sulfation can also be involved in the bioactivation of certain drugs to their 
therapeutically active form, such as minoxidil, and some N-hydroxy aromatic amines to their ultimate carcinogenic 
species [1,2]. In order to cope with substrates of such diverse chemical structure, multiple forms of STs have 
evolved. To date at least six different aryl STs and seven different forms of steroid/bile acid STs have been purified 
or characterised from rat liver [1]. While purification studies clearly demonstrate that multiple forms of ST exist, it 
has not been possible to totally charactersise this enzyme system using this approach. This is due to the fact that STs 
may often show identical mobilities on SDSpolyacrylamide gels and near identical protein sequences thus leaving 
doubt as to the purity of these preparations. In addition, limitations often associated with obtaining sufficient 
material from tissues or concern with the tedious process of conventional low-yielding purification procedures may 
ultimately affect enzyme quantity and quality. The limited availability of human tissue specimens is also likely to 
hamper the study of human STs, particularly the extrahepatic forms. 
An approach utilising molecular biology techniques can overcome many of these difficulties and has been 
used effectively to unravel the cytochrome P450, UDP-glucuronosyltransferase and glutathione transferase enzyme 
systems. For example, STs can be cloned, their cDNAs then inserted into eukaryotic or prokaryotic expression 
vectors and used to express active enzyme in cell culture, in techniques commonly known as cDNA-expression or 
heterologous expression. Enzyme activities and substrate specificities can then be analysed for the individually 
expressed ST isoforms with the knowledge that enzyme purity and integrity have not been compromised. With the 
recent availability of cDNAs encoding mammalian STs, heterologous expression now provides a means whereby 
these individual STs can be functionally and structurally characterised in detail. 
In this report we describe the use of the COS cell system to study the function of a rat [3] and human [4] 
aryl ST sharing 79% amino acid similarity. In addition we describe the use of an Escherichia coli (E. coli) 
expression system suitable for the purification of large quantities of a rat aryl ST as an antigen for the production of 
antibodies. 
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COS cell expression system 
 
A number of heterologous systems are currently available to express proteins from their respective cDNAs including 
yeast, insect cells and E. coli. However, the mammalian COS cell expression system has been the most extensively 
used for the study of ST enzymes [3,5-7]. A major advantage of the COS cell expression system is the ease of 
expressing functional protein and the low background of endogenous ST activity of the COS cells. Other advantages 
of this system are that it is a mammalian cell vector system and the process is simple and rapid. The COS cell line 
was derived by integration of an origin-defective mutant of simian virus 40 (SV40) viral DNA into the genome of 
African green monkey kidney cells [CV-1] [8]. The resultant COS cells produce SV40 T antigen which is required 
for viral replication. Thus, any transiently transfected plasmid DNA which contains the SV40 origin of replication is 
capable of replicating in COS cells. Transfected cells, therefore, will contain multiple copies of the plasmid which 
can synthesise the protein encoded by the inserted cDNA. However, a disadvantage of the COS system is that 
protein expression is generally maximal 48-72 h post-transfection and presumably due to the excessive burden 
placed on the transfected cells by the replicating plasmid, the cells eventually die (i.e the system is transient). 
A number of expression vectors have been used to successfully express cloned cDNAs in COS cells including the 
SV40 based vectors, pSVL (Pharmacia), pSVSPORT 1 (Gibco BRL) and p91023(B) [9], and the pCMV based 
vectors such as pCMV5 [10], as used in our laboratories. The pCMV mammalian expression vectors contain the 
promoter regulatory region of the human cytomegalovirus (Towne strain) major immediate early gene and are 
designed for use in essentially all cultured cells. They work extremely well in SV40-transformed simian COS cell 
lines and compared to the SV40-based vectors have been shown to give approximately a 5-10-fold greater level of 
expressed proteins including cytochrome P450s [11]. For this reason we chose to use the pCMV5 vector for 
expressing our cloned ST cDNAs. This vector was kindly provided by Dr Mark Stinsky, Department of 
Microbiology, School of Medicine, University of Iowa. 
A rat liver aryl ST cDNA was cloned from a rat liver Lambda cDNA library using the polymerase chain 
reaction technique as recently described by us [3]. To functionally characterise this ST, it was subcloned into the 
pCMV5 COS cell expression vector and expressed in COS-7 cells [3]. The cDNA-expressed ST protein catalysed 
the sulfation of phenol and p-nitrophenol as well as the monoamine neurotransmitter dopamine, and the common 
food additive, vanillin. The kinetics of sulfation of these substrates by this COS-expressed ST were best described 
by single enzyme Michaelis-Menten kinetics. The apparent Km for phenol, p-nitrophenol, vanillin and dopamine 
were 0.87 #M, 0.27/~M, 7.75/~M and 44.3/zM, respectively. For the substrates, phenol and dopamine, these 
apparent Kms were quite similar to the apparent Kms obtained in rat liver cytosol (phenol 1.54/zM; dopamine 19.1 
tzM) [3]. Activities in the COS cells transfected with vector alone (minus ST cDNA insert) were barely above 
background activity indicating the suitability of this expression 
system for determining enzyme function. 
We have also used the COS cell expression system to characterise a human liver aryl ST cDNA [4]. The 
protein encoded by this cDNA shares 79% similarity to the rat liver aryl ST characterised above. The human COS-
expressed ST, similarly to the expressed rat enzyme, could also catalyse the sulfation of the substrates phenol, 
pnitrophenol and dopamine. Kinetic analyses of these reactions showed the apparent Kms for these substrates 
(phenol 3.4/~M, p-nitrophenol 0.6/zM and dopamine 345 /~M) by the recombinant human ST were generally higher 
than for the recombinant rat ST, being almost 8-fold higher in the case for dopamine. These data indicate that even 
though there appear to be functional similarities between these expressed rat and human aryl STs subtle differences 
are apparent and hence caution should be exercised in extrapolating results with ST proteins from one species to 
another. The catalytic characteristics of the human enzyme, with a high affinity (low Kin) towards simple phenols 
and low affinity (high Km) towards monoamines such as dopamine, indicates that the recombinant protein is 
functionally quite similar to the phenolmetabolising form of phenol ST (P-PST) partially purified from human liver 
by other workers [12]. The other form of phenol ST characterised in human tissues, the monoamine-metabolising 
form (M-PST) [9,10], has quite high affinity for sulfating monoamines. Other means to differentiate these two human PST 
forms include the use of the ST inhibitor 2,6-dichloro-4-nitrophenol (DCNP) as well as thermal stability studies [12,13]. 
P-PST is sensitive to inhibition by DCNP and is relatively thermostable. In contrast, M-PST is quite resistant to DCNP 
inhibition and is relatively thermolabile. Preliminary experiments performed with the COS-expressed human ST described 
above indicate that it is sensitive to inhibition by DCNP as well as being relatively thermostable. These studies together 
with the substrate kinetic data described above are consistent with this human ST cDNA encoding P-PST. 
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E. coli expression system 
 
A particular limitation of the COS cell system is the low level of enzyme expressed, requiring the availability of sensitive 
assays to measure enzyme function. Furthermore, it is relatively expensive and tedious to obtain large amounts of enzyme 
using mammalian cell culture. More recently, bacterial expression systems have been developed for the expression of 
many proteins (including the xenobiotic metabolis- ing enzymes), with these generally being devoid of many of the 
limitations associated with mammalian expression systems [14]. Expression levels obtained in E. coli have been 
reported as high as 50-100 mg per 1 of culture for some proteins, this being several orders of magnitude higher than 
would be obtained in COS cells. 
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We were primarily interested in using E. coli as an expression system to synthesise sufficient ST protein such that it 
could be purified from other E. coli proteins and used as antigen for preparing antibodies. The availability of an 
antibody would enable us to measure the expression of ST proteins in a number of systems including, tissue 
preparations incorporating Western blotting and immunohistochemistry techniques, as well as detecting expression 
of ST protein in eDNA transfection experiments such as in the COS cells described above. This approach of 
generating antibodies again avoids all the problems associated with having to purify protein from animal or human 
sources as described earlier. We used the E. coli expression system 'QIAexpress', available commercially in 'kit' 
form (Qiagen Inc., Chatsworth, CA, USA), for the expression and purification of recombinant proteins (Fig. 1). An 
ideal feature of this system is the ability to purify the expressed protein from other E. coli proteins in a one step 
procedure. This is achieved by the addition of an affinity tag of six consecutive histidine residues (6 x His tag) to the 
expressed protein which can then be purified on the unique Nicket-NTA (Nitrilo-Tri-Acetic acid) resin which has 
remarkable selectivity for proteins with a 6 x His tag. This means that tagged proteins can be efficiently purified to 
greater than 95% purity in just one step. To investigate the suitability of this system for ST proteins we used the rat 
aryl ST eDNA previously isolated by us [3]. This eDNA was inserted into the 'QIAexpress' bacterial vector pQE-11 
(this vector has the 6 x His tag sequence incorporated upstream of the multiple cloning site) and transformed into the 
E. coti strains M 15[pREP4] and SG13009[pREP4] provided (Qiagen). Protein expression from the pQE vector was 
induced by the addition of isopropyl-~3-D-thiogalactopyranoside (IPTG) and purification was generally as per the 
manufacturers instructions (see Fig. 2 legend for details). However, denaturing conditions had to be used to 
solubilise the expressed ST protein, which appears to be present within insoluble inclusion bodies in the E. coli. This 
required the use of 6M guanidine HC1, but because the interaction between the Ni-NTA resin and the 6 x His tag is 
independent of protein structure, purification is unaffected by strong denaturants. This is a clear advantage of the 
above E. coli expression and purification system over others such as pGEX (Pharmacia) which use glutathione S-
transferase as the affinity 'tail' and cannot be used under such denaturing conditions. 
The results of a typical ST expression and purification protocol are shown in Fig. 2. As can be seen from 
this figure the level of expression we obtained was high (in the order of 25 mg purified rat ST protein per 500 ml 
culture were obtained), as evidenced by the marked induction of ST protein (~ 41 kDa) by IPTG, and from the SDS-
PAGE analysis the eluted protein appears greater than 95% pure. The purified recombinant ST protein was used as 
antigen to generate antibodies in rabbits, and as can be seen in the Western immunoblot in Fig. 3, is suitable for 
detecting the expression of ST protein in rat cytosolic preparations and in COS cell expression experiments. It 
should be noted that the 6 x His tagged ST protein detected in Fig. 3 runs at a slightly higher molecular weight than 
the COS-expressed ST and the protein detected in rat liver cytosol, this being due the presence of the 6 × His 'tail'. 
Antibodies specific to particular forms of ST proteins could also be prepared using the above described system by 
expressing tagged peptide fragments that are unique to the protein of interest, Clearly, the E. coli expression and 
purification system is an extremely versatile tool for preparing antigens for antibody generation, and we are 
currently using this approach with our human ST cDNAs to develop tools to investigate the tissue expression and 
distribution of these encoded proteins. 
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We were also particularly interested in whether E. coli expression may also provide an alternative to the COS celt 
system for undertaking functional analyses, considering the levels of expression are markedly higher in E. coli. 
Unfortunately, as mentioned above, during investigation of the expression of the ST protein in the above 
'QIAexpress' system, the protein was present in E. coli as insoluble inclusion bodies, as evidenced by SDS-PAGE 
analysis (data not shown). This required the use of strong denaturing agents to solubilise the protein, affecting the 
ability to determine enzyme function. We tried measuring catalytic function of rat aryl ST protein in washed whole 
E. coli cells after IPTG induction and did find activity towards phenol sulfation however, the activity was not higher 
than that obtained for COSexpressed rat ST protein. In addition, background activity was appreciably higher in 
untransformed E. coli cells. Sonication and/or lysozyme treatment of cells (to lyse cells) failed to increase activity. 
These results suggest that although extensive inclusion body formation exists a small proportion is soluble and 
hence active. Attempts to decrease inclusion body formation and increase soluble protein by altering induction 
temperature (30°C vs. 37°C) and strain of E. coli (SGI3009[pREP4] versus M15[pREP4]) had little affect on 
improving activity. Other strains of E. coli as well as methods to regenerate (i.e., refold) the solubilised protein are 
currently under investigation in this laboratory to enable generation of large amounts of functionally active pure 
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protein. This type of expression system also seems the most likely to be able to generate sufficient amounts of 
enzyme for undertaking the crystallisation of ST proteins. This will increase enormously our understanding of the 
structure/function relationships of ST proteins. 
In conclusion, we have shown that the COS cell expression system is a suitable heterologous system to 
study the catalytic function of cloned mammalian ST cDNAs. This is evident from the successful characterisation of 
a rat and human aryl ST in our laboratories. The use of this eukaryotic expression system also makes possible 
studies which can give insight into the structural basis of ST substrate specificity. Examples include the use of 
studies which identify specific amino acids and domains of ST proteins thought to be involved in substrate or 
cofactor binding by expressing in COS cells altered STs engineered by site-directed mutagenesis or chimeric protein 
constructs. Although the E. coli expression system we employed was not entirely suitable for functional analyses of 
STs it was found to be extremely useful for the generation of large amounts of ST suitable as antigen for antibody 
production. The basis of these techniques of heterologous expression now provides us with the means to make 
significant inroads into the structural and functional characterisation of cloned STs as well as their expression and 
distribution in a range of tissues. 
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